Screener
Indivior Pharmaceuticals, Inc. INDV Operating Income
Operating Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028850
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Selling, general and administrative | 124 | 133 |
| Research and development | 16 | 22 |
| Total operating expenses | 139 | 156 |
| Operating income | 137 | 66 |
| Other (income) and expenses: | ||
| Interest (income) | (3) | (4) |
| Interest expense | 7 | 12 |
| Loss on debt extinguishment | 18 | — |
Item 1. Unaudited Condensed Financial Statements.
FAQ
- What is Indivior Pharmaceuticals, Inc.'s operating income?
- Indivior Pharmaceuticals, Inc. (INDV) reported operating income of $137M in Q1 2026.
- How has Indivior Pharmaceuticals, Inc.'s operating income changed year-over-year?
- Indivior Pharmaceuticals, Inc.'s operating income increased by 107.6% year-over-year, from $66M to $137M.
- What is the long-term trend for Indivior Pharmaceuticals, Inc.'s operating income?
- Over 3 years (2022 to 2025), Indivior Pharmaceuticals, Inc.'s operating income has grown at a 50.4% compound annual growth rate (CAGR), from -$77M to $262M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Indivior Pharmaceuticals, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude